Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials

BACKGROUND: Hyperglycemia and hypercholesterolemia are class effects of mammalian target of rapamycin inhibitors. The purpose of this study was to characterize safety and efficacy of patients with metastatic renal cell carcinoma (mRCC) treated with everolimus in RECORD-1 (REnal Cell cancer treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Bono, Petri, Oudard, Stephane, Bodrogi, Istvan, Hutson, Thomas E., Escudier, Bernard, Machiels, Jean-Pascal, Thompson, John A., Figlin, Robert A., Ravaud, Alain, Basaran, Mert, Porta, Camillo, Bracarda, Sergio, Brechenmacher, Thomas, Lin, Chinjune, Voi, Maurizio, Grunwald, Viktor, Motzer, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Original Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063024/
https://www.ncbi.nlm.nih.gov/pubmed/27287020
http://dx.doi.org/10.1016/j.clgc.2016.04.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063024/
https://www.ncbi.nlm.nih.gov/pubmed/27287020
http://dx.doi.org/10.1016/j.clgc.2016.04.011

Ejemplares similares